A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224

Steatohepatitis, Nonalcoholic Clinical Trial

Official title:
An Adaptive Two-Part Phase 2, Multi-Center, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224 Administered Once Monthly in Adult Subjects With Confirmed Non-Alcoholic Steatohepatitis

Status Completed

Clinical Trial Summary

The purpose of this study is to assess the effect of multiple ION224 doses when administered by subcutaneous (SC) injection for 49 weeks (end of the treatment [EOT]) on non-alcoholic steatohepatitis (NASH) histologic improvement and to assess the effect on liver steatosis by magnetic resonance imaging-determined proton density fat fraction (MRI-PDFF), additional changes in NASH histologic features, liver biochemistry tests, and plasma lipid profile.

Clinical Trial Description

This is a Phase 2, double-blind, randomized, placebo-controlled study of ION224 in up to 150 participants. The study consists of 3 periods: 1) Screening Period: Week -8 to Week -1 (up to 8 weeks); 2) Treatment Period up to Week 49; and 3) Post-Treatment Period: Week 50 to Week 62 (12 weeks). Initially, 48 patients will be enrolled in three different dose cohorts to receive ION224 or placebo every four weeks and based on safety and effects on liver steatosis (assessed at Week 15), two dose cohorts will be selected to be expanded. After dose selection, an additional 102 patients will be enrolled in the 2 selected dose cohorts and will receive ION224 or placebo for up to 49 weeks. Participants in the 3rd cohort (not selected) will continue to complete up to 49 weeks of treatment without any cohort expansion. ;

Study Design

Related Conditions & MeSH terms

Fatty Liver
Non-alcoholic Fatty Liver Disease
Steatohepatitis, Nonalcoholic

Clinical Trial Details

NCT number	NCT04932512
Study type	Interventional
Source	Ionis Pharmaceuticals, Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	June 17, 2021
Completion date	February 28, 2024

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04861012` - Screening for Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD) at Al-Rajhy Hospital Nutrition Clinic. Assiut, Egypt	N/A
Completed	`NCT03915002` - Integrated Approaches for Identifying Molecular Targets in Liver Disease
Recruiting	`NCT06400771` - Safety of DNP007 in Healthy Subjects	Phase 1
Recruiting	`NCT06302049` - Clinical Study Evaluating the Safety and Efficacy of Esomeprazole in Treatment of Non-alcoholic Steatohepatitis	Phase 1/Phase 2
Recruiting	`NCT04707651` - Formula Diet Treatment for NASH Patients.	N/A
Terminated	`NCT04175392` - Effect of Probiotics in Non-alcoholic Fatty Liver Disease and Steatohepatitis	Phase 1/Phase 2
Recruiting	`NCT04785937` - Accuracy of Imaging Techniques in Diagnosing Steatohepatitis and Fibrosis in NAFLD Patients	N/A
Active, not recruiting	`NCT05946330` - Nutritional Intervention IN Nash NON-ALCOHOLIC (NAFLD).	N/A
Terminated	`NCT04284371` - The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) Pediatric Patients
Completed	`NCT04080947` - The Leukotriene Receptor Antagonist Montelukast in the Treatment of Non-alcoholic Steatohepatitis	Phase 1/Phase 2